Boston Scientific (NYSE:BSX) Director Ernest Mario unloaded 10,000 shares of Boston Scientific stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $13.55, for a total transaction of $135,500.00. Following the sale, the director now directly owns 327,855 shares of the company’s stock, valued at approximately $4,442,435. Boston Scientific Corporation (NYSE:BSX) shares after opening at $13.48 moved to $13.71 on last trade day and at the end of the day closed at $13.65. Company price to sales ratio in past twelve months was calculated as 2.53 and price to cash ratio as 83.25. Boston Scientific Corporation (NYSE:BSX) showed a positive weekly performance of 5.57%.
ACADIA Pharmaceuticals (NASDAQ:ACAD) Director Torsten Rasmussen unloaded 30,000 shares of the stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $21.98, for a total value of $659,400.00. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares advanced 0.83% in last trading session and ended the day on $19.44. ACAD return on equity ratio is recorded as -24.30% and its return on assets is -21.70%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) yearly performance is 59.61%.
Sangamo Biosciences (NASDAQ:SGMO) CFO Henry Ward Wolff sold 15,000 shares of the company’s stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $15.72, for a total transaction of $235,800.00. Following the completion of the transaction, the chief financial officer now directly owns 225,347 shares of the company’s stock, valued at approximately $3,542,455. Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares moved down -1.89% in last trading session and was closed at $13.99, while trading in range of $13.74 – $14.54. Sangamo Biosciences, Inc. (NASDAQ:SGMO) year to date (YTD) performance is 0.72%.
XOMA Corp (NASDAQ:XOMA) CEO John Varian sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.03, for a total transaction of $60,300.00. Following the transaction, the chief executive officer now directly owns 270,035 shares in the company, valued at approximately $1,628,311. XOMA Corp (NASDAQ:XOMA) weekly performance is -2.09%. On last trading day company shares ended up $4.21. XOMA Corp (NASDAQ:XOMA) distance from 50-day simple moving average (SMA50) is -34.17%. Analysts mean target price for the company is $9.33.